A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

NCT06064890 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Frontotemporal Dementia
FTD
FTD-GRN
Dementia, Frontotemporal

Interventions

PROCEDURE: Intrathalamic AAV.PGRN administration
GENETIC: Intrathalamic AVB-101

Sponsor

AviadoBio Ltd